AbbVie
Global biopharmaceutical company developing medicines
M&A Integration Lead - Research & Development
+ Long-term incentive program
About the job
- A Bachelor's degree in Business or Computer Science or a related discipline with 7 years of experience, a Master's degree with 6 years of experience, or a PhD with 2 years of experience.
- Experience leading a portfolio of business applications and large, complex cross-functional global information technology implementations, including strong financial management experience.
- Experience working on mergers, acquisitions, divestitures, and collaboration.
- Experience integrating Research and Development systems from acquisitions.
- Experience with Business Continuity Planning after mergers and acquisitions integration.
- Skill in leveraging generative and agentic artificial intelligence to reimagine or improve a process or capability, with experience leading and implementing multiple projects that drove speed, efficiency, or cost savings.
- Experience working with Research and Development business applications such as Veeva solutions, laboratory information management systems, electronic laboratory notebooks, clinical trial systems such as clinical trial management systems, scientific data management platforms, laboratory systems, research portfolio management tools, and document management systems.
- Strong project management, stakeholder engagement, financial management, business systems applications, and delivery of complex cross-functional global programs.
- Serve as the Information Research mergers and acquisitions integration lead for multiple company-wide and Research and Development deal transactions, with responsibility for overall program health, financials, and reporting.
- Establish a cross-functional Information Research team for each deal that is fully accountable for integrating or divesting people, data, and systems.
- Develop business relationships and integrate activities with other business technology organizations to support successful integration execution and long-term project execution.
- Manage relationships between business technology organizations, Research and Development business teams, and Finance to ensure effective communication.
- Broker services within Business Technology Solutions on behalf of customers, coordinate a portfolio of solutions, and identify interdependencies.
- Work with Research and Development business and Business Technology Solutions functional leads to define business decisions, solution options, and recommendations for each deal based on the deal model, size, complexity, risk, and speed to business value.
- Collaborate with other business technology organizations to remain current on project status, inform management and stakeholders of progress, keep managers and stakeholders aware of user issues, and resolve conflicts proactively.
- Escalate and drive resolution of risks and issues across functions.
- Present Information Research updates in Information Research leadership forums and Research and Development integration forums.
- Lead continuous improvement projects to increase speed and agility in Business Technology Solutions mergers and acquisitions services and capabilities.
- Identify and implement innovative artificial intelligence solutions and capabilities to challenge the status quo and deliver value to the business faster.
- Ensure compliance with Business Technology Solutions system life cycle, corporate, and divisional policies and procedures.
- At least 6 years of experience leading a portfolio of business applications and large, complex cross-functional global information technology implementations, including strong financial management experience.
- At least 6 years of experience working on mergers, acquisitions, divestitures, and collaboration.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $16.99 billion, up 10.2%, driven by Skyrizi and Rinvoq.
- AbbVie completed the $10.9 billion Apogee deal on September 3, 2026.
- September 2026 data kept etentamig, bretisilocin, and Crohn’s expansion on track.
What critics are saying
- Humira sales fell 36.1% in Q2 2026, exposing lingering erosion pressure.
- AbbVie cut 85 Irvine jobs on May 19, 2026, signaling ongoing efficiency pressure.
- Atogepant patent fights against Apotex, Macleods, and Dr. Reddy’s threaten Qulipta cash flows.
What makes AbbVie unique
- AbbVie’s 2026 engine is Skyrizi and Rinvoq, not Humira.
- It owns durable immunology IP, with Rinvoq U.S. entry expected after April 2037.
- Apogee acquisition added dermatology and respiratory assets on September 3, 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%AbbVie tees up brain health campaign with PGA TOUR. Key summary: * AbbVie has become the official pharmaceutical sponsor of the US's PGA TOUR. * Birdies for Brain Health will fund organisations supporting brain health patients. * Golfer Gary Woodland will help raise awareness through his personal brain health story. AbbVie has been named the official pharmaceutical sponsor of the PGA TOUR and 2026 Presidents Cup, as the drugmaker launches a new campaign to raise awareness and support for people living with brain health conditions. The multi-year partnership will see AbbVie roll out its 'Birdies for Brain Health' campaign, which will use professional golf to generate donations for patient advocacy organisations working across migraine, mental health conditions and Parkinson's disease. The campaign will debut at the 2026 Presidents Cup at Medinah Country Club in Illinois, close to AbbVie's global headquarters in North Chicago. Turning birdies into brain health support. To mark the launch, AbbVie will make a donation recognising the more than one in three people globally affected by a neurological disorder, with funds shared between six patient organisations. These include the American Migraine Foundation, National Headache Foundation, Mental Health America, National Alliance on Mental Illness, Michael J. Fox Foundation for Parkinson's Research and Parkinson's Foundation. From 2027, the initiative will expand across PGA TOUR Signature Events and the FedExCup Playoffs, with AbbVie making donations for every birdie scored. The partnership comes as AbbVie continues to strengthen its presence in neuroscience, where its portfolio spans psychiatry, migraine and pain, movement disorders and neurodegenerative diseases. Just last week, the company announced the successful phase 3 trial of its menstrual migraine preventative drug, atogepant. Tracie Haas, Senior Vice President, Corporate Affairs, AbbVie, said neurological and mental health conditions can have an impact extending beyond patients to their families and wider support networks. "Through our partnership with the PGA TOUR, we have a unique opportunity to elevate patient and care partner voices, support patient advocacy organisations and raise awareness of the critical need for continued research, innovation and care," she said. Gary Woodland joins campaign. AbbVie will also work with professional golfer Gary Woodland, 2019 US Open champion and one of the US captain's assistants for the 2026 Presidents Cup, to promote the campaign through storytelling and engagement. Woodland underwent surgery in 2023 to remove a benign brain lesion and has since spoken publicly about the physical, mental and emotional challenges he experienced during his recovery. "My experience has shown me how important awareness, support and a strong community can be when someone is facing a health challenge," Woodland said. He added that the campaign offers an opportunity to use golf's platform to support organisations advancing science and patient advocacy. The partnership represents a new route for AbbVie to connect its neuroscience ambitions with patient advocacy, while tapping into the PGA TOUR's global audience to broaden conversations around brain health. Press play to listen to this content
AbbVie reported revenue of $61.2 billion in FY 2025, up 8.6% year-over-year, with net income of $4.2 billion. The pharmaceutical giant generated free cash flow of $17.8 billion despite a debt-to-equity ratio of -21.1x. Growth products Skyrizi and Rinvoq are offsetting competition for older medications. CRISPR Therapeutics saw revenue fall 90% to $3.5 million in FY 2025 and posted a net loss of $581.6 million. The gene-editing company burned $345.9 million in cash but maintains a conservative balance sheet with a 0.2x debt-to-equity ratio and 13.3x current ratio. AbbVie faces patent expiry risks and pricing pressures, whilst CRISPR depends heavily on partner Vertex for commercialisation. CRISPR's Casgevy gene therapy recently gained FDA approval for children aged two and above, expanding its patient population.
Millennium Management, led by billionaire Israel "Izzy" Englander, recently increased its AbbVie stake by more than double to 1.5 million shares worth around $380 million. The fund also took a new position in SpaceX, purchasing 17.6 million shares valued at nearly $3 billion. AbbVie, a diversified pharmaceutical company, offers products treating chronic conditions and cancers. Its key drugs Skyrizi and Rinvoq generated $9.99 billion and $4.64 billion respectively in the first half of 2026. The company pays a dividend yield of 2.7%, with its annual dividend growing from $2.28 in 2016 to $6.83 currently. SpaceX leads in space launches and satellite communications through Starlink. The company reported 92% year-over-year revenue growth to $7.8 billion in the second quarter.
Modivcare names new CEO of personal care services; LifeCare appoints new COO. Modivcare names new CEO of personal care services, chief corporate affairs officer. Modivcare named Marshalina "Marsha" Ramos CEO of the personal care services (PCS) business on Sept. 8, where she will oversee the company's PCS portfolio. Prior to joining Modivcare, Ramos served as founder and CEO of home care and hospice advisory firm Visionary Group. She also acted as president and chief operating officer of home-based care provider Premier Home Health Care and held numerous senior roles at home care provider VNS Health. "[Ramos] has built and stabilized multi-state home care operations, navigated complex regulatory and managed care environments and earned the loyalty of the teams she has led," Modivcare Board of Managers Chair Leslie Norwalk said in a statement. "With Marsha's addition to the Modivcare team, each of our businesses is now led by a seasoned executive with deep industry expertise and a strong understanding of the markets they serve." The company tapped Matt Williams to serve as chief corporate affairs officer effective Sept. 1. He will oversee Modivcare's corporate reputation and communications, regulatory affairs and public policy and focus on bolstering the company's stakeholder engagement and advocacy. Williams previously served as vice president of government affairs at McKesson, a medical supplies and pharmaceutical healthcare company, and major pharmaceutical manufacturer AbbVie. "I'm honored to join Modivcare at an important time for the company," Williams said in a statement. "I look forward to working alongside teams across the organization to strengthen our reputation, deepen relationships with policymakers, clients and other stakeholders, and advance our mission." Denver-based Modivcare provides nonemergency medical transportation, personal care, remote monitoring and integrative supportive care across 35 states. LifeCare Home Health & Hospice Family appoints new chief operating officer. Dr. Nasser Khan joined LifeCare Home Health & Hospice Family as president and COO, where he will manage operations across the company's portfolio and scale growth and integrations. Khan previously served as COO of behavioral health company Acadia Healthcare, in addition to roles at specialty pharmacy solutions provider Shields Health Solutions, kidney dialysis provider DaVita Kidney Care, preventive diagnostics clinic Biograph and global management consulting company McKinsey & Company. "Dr. Khan brings a rare combination of clinical insight, operational experience and demonstrated leadership at scale," LifeCare Home Health & Hospice Family CEO Dean Alverson said in a statement. "As LifeCare continues to grow, his experience developing teams, strengthening operations and bringing organizations together will be invaluable." Irving, Texas-based LifeCare Home Health & Hospice Family offers home health, hospice and in-home care throughout 39 locations in Texas, Florida, Georgia, Nevada and Arizona. BrightSpring taps Alliance VP as vice president of federal government relations. Hillary Loeffler joined BrightSpring Health Services (Nasdaq: BTSG) as vice president of federal government relations in August 2026, according to her LinkedIn profile. Before joining BrightSpring, Loeffler served as vice president of policy and regulatory affairs for the National Alliance for Care at Home and held various roles at the Centers for Medicare & Medicaid Services (CMS) for over 13 years. Louisville, Kentucky-based BrightSpring Health Services provides home health, personal care, infusions and specialty pharmaceuticals, hospice and other services throughout all 50 states. Senior1Care names cate Palace president of Northeast region. Cate Palace will serve as the president of the Northeast region for Senior1Care, where she is charged with handling growth and operations in three Indiana cities. Palace has over 20 years of experience including leading home care, skilled nursing, assisted rehabilitation and other agencies providing services for older adults. "Palace understands senior care from both a clinical and operational perspective and recognizes the role relationships play in earning the trust of families, healthcare partners and the communities we serve," Senior1Care CEO Kyle Bossung said in a statement. "I'm grateful she chose to bring that perspective to Senior1Care and look forward to having her as part of our leadership team." Senior1Care, based in Mishawaka, Indiana, provides personal care and companionship services across the Angola, Elkhart, Fort Wayne, Indianapolis, South Bend and Warsaw regions of Indiana. Porter appoints Jeff Fox as chief growth officer. Porter named Jeff Fox chief growth officer. He is charged with leading the company's growth strategy, relationships with health plans, strategic partnerships and technology expansion. Baltimore-based Porter is a healthcare IT and services platform that offers care coordination and in-home care assessments for families, individuals, payers and at-risk providers. Fox previously led Atrio Health Plans as CEO, where he aided the firm's expansion into new markets, and oversaw Gorman Health Group for 17 years as president and CEO. "Jeff knows this business and the people it serves," Porter Founder, CEO and Chairman John Criswell said in a statement. "He understands how health plans work, the pressures they face, and what is at stake for the people who depend on them. That experience will help Porter grow with purpose and deliver at a greater scale." Companies featured in this article: MK Manoylov is a Senior Reporter at Home Health Care News. Their work has appeared in publications including WebMD, Business Insider and LiveScience, in addition to governmental reports from the U.S. Department of the Treasury. MK earned a master's degree in journalism in the Science, Health and Environmental Reporting (SHERP) from New York University.
AbbVie has dramatically shifted its focus away from Humira, its once-flagship drug now facing biosimilar competition. On the company's July 2026 earnings call, Humira received just one sentence, noting global sales of $706 million, down 36.1% operationally but in line with expectations. This marks a stark change from previous quarters when management detailed the reasons behind Humira's decline, including biosimilar competition and molecule compression in the US market. AbbVie now emphasises growth drivers instead. Skyrizi generated $5.5 billion in Q2 2026, whilst Rinvoq exceeded $2.5 billion, both growing above 20% operationally. The company also acquired Apogee Therapeutics in September 2026. Despite the reduced attention, Humira still contributes approximately 4% of AbbVie's quarterly revenue of nearly $17 billion, though management no longer publicly projects its ultimate decline trajectory.